FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979697906> ?p ?o ?g. }

• W2979697906 abstract "Abstract Abstract 4253 Cytotoxic T lymphocytes (CTLs) are presumed to kill the relevant antigen-expressing leukemia cells including leukemic stem cells, which display intrinsic resistance against tyrosine kinase inhibitors such as imatinib in CML patients. In order to clarify the safety and effectiveness of WT1 peptide vaccination for the patients with CML, we started WT1 peptide vaccination in combination with imatinib therapy for a CML patient who could not acquire a major molecular response by the administration of imatinib. In addition, we tried to evaluate the kinetics of WT1-specific CTLs in peripheral blood (PB) during WT1 peptide vaccination. A 51 years-old male with CML in chronic phase had been treated with 400 mg imatinib for 4 years. BCR-ABL transcripts decreased transiently to less than 700 copies in 1 μg RNA (3-log reduction: 300 copies in 1 μg RNA extracted from PB cells; median in our laboratory) but gradually increased to more than 1,000 copies thereafter. Since the patient was HLA-A*2402+ and an informed consent was obtained, HLA-A*2402-restricted 9mer WT1 peptides (CYTWNQMNL; a.a. 235-243), which had been identified to possess an anti-tumor immunogenicity, were administered subcutaneously at the dose of 1 mg/day every 2 weeks in combination with 400 mg imatinib for first 5 months and thereafter every 4 weeks for 12 months. No adverse effects due to WT1 peptide vaccination was observed except for skin induration and redness at the sites of WT1 peptide injection. Although BCR-ABL transcripts increased up to more than 2,000 copies after transient decrease to less than 1,000 copies by the administration of WT1 peptides every 2 weeks, the transcripts have decreased to less than 500 copies by the administration of WT1 peptides every 4 weeks. The appearance of WT1-specific CTLs in PB was confirmed by evaluating the frequency of MHC/WT1 tetramer+CD8+ T cells by using MLPC (mixed lymphocyte peptide culture). MLPC was performed by culturing 1-3 ×105 PB mononuclear cells (MNCs) in 200 l of 5% autologous serum-containing medium with 10 μg WT1 peptides in 96 well plates. Frequency of MHC/WT1 tetramer+ cells in PB-CD8+ cells was calculated by the following formula. Number of wells containing a lump of tetramer+CD8+ cells / [(Number of PB-MNCs seeded in a well of MLPC) x (total number of wells for MLPC) x (ratio of PB-CD8+ cells in PB-MNCs)]. Although WT1-specific CTLs were not detected in PB before WT1 peptide vaccination, the CTLs appeared after the second vaccination and maintained at the level of nearly 15/106 CD8+ cells thereafter. The MHC/WT1 tetramer+ cells showed cytotoxicity against only leukemia cells expressing WT1 and HLA-A*2402. The cytotoxicity was blocked clearly by adding unlabeled cold target cells in cold inhibition test and blocked also by antibodies against MHC class I but not by antibodies against MHC class II. In vitro study demonstrated that the stimulation with WT1 peptides made WT1-specific CTLs, which were generated by MLPC, less reactive to MHC/WT1 tetramers and the unreactivity lasted at least for 2 weeks. The present study showed that WT1 peptide vaccination for an imatinib-pretreated CML patient is feasible and effective, which is due to the generation of WT1-specific CTLs with cytotoxicity against WT1-expressing leukemia cells. In addition, since the CTLs are suggested to get tolerant to WT1 peptides presented by leukemia cells by the exposure with WT1 peptides, the interval of peptide administration has to be considered for the clinical efficacy of peptide vaccination. The present findings including in vivo and in vitro studies revealed that the administration of the peptides every 4 weeks is superior to every 2 weeks. Disclosures: No relevant conflicts of interest to declare." @default.
• W2979697906 created "2019-10-18" @default.
• W2979697906 creator A5014020322 @default.
• W2979697906 creator A5018408622 @default.
• W2979697906 creator A5028311611 @default.
• W2979697906 creator A5032005435 @default.
• W2979697906 creator A5036433330 @default.
• W2979697906 creator A5036489000 @default.
• W2979697906 creator A5047353543 @default.
• W2979697906 creator A5055227838 @default.
• W2979697906 creator A5065661878 @default.
• W2979697906 creator A5068336316 @default.
• W2979697906 creator A5082252001 @default.
• W2979697906 creator A5083034275 @default.
• W2979697906 creator A5086415382 @default.
• W2979697906 creator A5090850687 @default.
• W2979697906 date "2009-11-20" @default.
• W2979697906 modified "2023-09-28" @default.
• W2979697906 title "Effectiveness of WT1 Peptide Vaccination Combined with Imatinib in a Patient with CML in Chronic Phase." @default.
• W2979697906 doi "https://doi.org/10.1182/blood.v114.22.4253.4253" @default.
• W2979697906 hasPublicationYear "2009" @default.
• W2979697906 type Work @default.
• W2979697906 sameAs 2979697906 @default.
• W2979697906 citedByCount "0" @default.
• W2979697906 crossrefType "journal-article" @default.
• W2979697906 hasAuthorship W2979697906A5014020322 @default.
• W2979697906 hasAuthorship W2979697906A5018408622 @default.
• W2979697906 hasAuthorship W2979697906A5028311611 @default.
• W2979697906 hasAuthorship W2979697906A5032005435 @default.
• W2979697906 hasAuthorship W2979697906A5036433330 @default.
• W2979697906 hasAuthorship W2979697906A5036489000 @default.
• W2979697906 hasAuthorship W2979697906A5047353543 @default.
• W2979697906 hasAuthorship W2979697906A5055227838 @default.
• W2979697906 hasAuthorship W2979697906A5065661878 @default.
• W2979697906 hasAuthorship W2979697906A5068336316 @default.
• W2979697906 hasAuthorship W2979697906A5082252001 @default.
• W2979697906 hasAuthorship W2979697906A5083034275 @default.
• W2979697906 hasAuthorship W2979697906A5086415382 @default.
• W2979697906 hasAuthorship W2979697906A5090850687 @default.
• W2979697906 hasConcept C125418893 @default.
• W2979697906 hasConcept C126322002 @default.
• W2979697906 hasConcept C147483822 @default.
• W2979697906 hasConcept C154317977 @default.
• W2979697906 hasConcept C159047783 @default.
• W2979697906 hasConcept C170493617 @default.
• W2979697906 hasConcept C195616568 @default.
• W2979697906 hasConcept C202751555 @default.
• W2979697906 hasConcept C203014093 @default.
• W2979697906 hasConcept C22070199 @default.
• W2979697906 hasConcept C2776789287 @default.
• W2979697906 hasConcept C2777583451 @default.
• W2979697906 hasConcept C2778729363 @default.
• W2979697906 hasConcept C2780868878 @default.
• W2979697906 hasConcept C3019892230 @default.
• W2979697906 hasConcept C42362537 @default.
• W2979697906 hasConcept C55493867 @default.
• W2979697906 hasConcept C71924100 @default.
• W2979697906 hasConcept C86803240 @default.
• W2979697906 hasConceptScore W2979697906C125418893 @default.
• W2979697906 hasConceptScore W2979697906C126322002 @default.
• W2979697906 hasConceptScore W2979697906C147483822 @default.
• W2979697906 hasConceptScore W2979697906C154317977 @default.
• W2979697906 hasConceptScore W2979697906C159047783 @default.
• W2979697906 hasConceptScore W2979697906C170493617 @default.
• W2979697906 hasConceptScore W2979697906C195616568 @default.
• W2979697906 hasConceptScore W2979697906C202751555 @default.
• W2979697906 hasConceptScore W2979697906C203014093 @default.
• W2979697906 hasConceptScore W2979697906C22070199 @default.
• W2979697906 hasConceptScore W2979697906C2776789287 @default.
• W2979697906 hasConceptScore W2979697906C2777583451 @default.
• W2979697906 hasConceptScore W2979697906C2778729363 @default.
• W2979697906 hasConceptScore W2979697906C2780868878 @default.
• W2979697906 hasConceptScore W2979697906C3019892230 @default.
• W2979697906 hasConceptScore W2979697906C42362537 @default.
• W2979697906 hasConceptScore W2979697906C55493867 @default.
• W2979697906 hasConceptScore W2979697906C71924100 @default.
• W2979697906 hasConceptScore W2979697906C86803240 @default.
• W2979697906 hasLocation W29796979061 @default.
• W2979697906 hasOpenAccess W2979697906 @default.
• W2979697906 hasPrimaryLocation W29796979061 @default.
• W2979697906 hasRelatedWork W1985628756 @default.
• W2979697906 hasRelatedWork W2109652607 @default.
• W2979697906 hasRelatedWork W2293366814 @default.
• W2979697906 hasRelatedWork W2321635343 @default.
• W2979697906 hasRelatedWork W2330691552 @default.
• W2979697906 hasRelatedWork W2342647895 @default.
• W2979697906 hasRelatedWork W2470249916 @default.
• W2979697906 hasRelatedWork W2470646853 @default.
• W2979697906 hasRelatedWork W2528484761 @default.
• W2979697906 hasRelatedWork W2554850471 @default.
• W2979697906 hasRelatedWork W2556402107 @default.
• W2979697906 hasRelatedWork W2574102047 @default.
• W2979697906 hasRelatedWork W2584364734 @default.
• W2979697906 hasRelatedWork W2594484034 @default.
• W2979697906 hasRelatedWork W2595739978 @default.
• W2979697906 hasRelatedWork W2979816540 @default.
• W2979697906 hasRelatedWork W2979900345 @default.
• W2979697906 hasRelatedWork W2980273656 @default.
• W2979697906 hasRelatedWork W2980336992 @default.
• W2979697906 hasRelatedWork W3029626531 @default.

• next